{"id":29245,"date":"2025-03-14T17:10:13","date_gmt":"2025-03-14T09:10:13","guid":{"rendered":"https:\/\/flcube.com\/?p=29245"},"modified":"2025-03-14T17:10:17","modified_gmt":"2025-03-14T09:10:17","slug":"salipro-biotech-and-boehringer-ingelheim-collaborate-on-drug-development-for-membrane-proteins","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=29245","title":{"rendered":"Salipro Biotech and Boehringer Ingelheim Collaborate on Drug Development for Membrane Proteins"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Sweden-based Salipro Biotech AB announced a research and license agreement with German pharmaceutical giant Boehringer Ingelheim. The collaboration aims to advance the development of novel drugs targeting G protein-coupled receptors (GPCRs), ion channels, transporters, and other integral membrane proteins, focusing on treatment areas such as mental health and cardio-renal-metabolic diseases.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Collaboration Details<\/strong><br>Under the agreement, Salipro Biotech\u2019s proprietary Salipro platform technology will be utilized to enable the use of membrane proteins in their native forms for drug discovery programs. Boehringer Ingelheim will conduct biophysical and structural studies, including cryo-electron microscopy (cryoEM), to identify potential therapeutic candidates. This integrated approach leverages Salipro&#8217;s innovative platform and Boehringer Ingelheim&#8217;s extensive drug development expertise.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Financial Terms<\/strong><br>Salipro Biotech will receive undisclosed research payments and option payments under the agreement. The company is also eligible for downstream success-based milestone payments, reflecting the potential value of the collaboration in advancing novel therapeutics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sweden-based Salipro Biotech AB announced a research and license agreement with German pharmaceutical giant Boehringer&#8230;<\/p>\n","protected":false},"author":1,"featured_media":29247,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[390,3585],"class_list":["post-29245","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-boehringer-ingelheim","tag-salipro-biotech"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Salipro Biotech and Boehringer Ingelheim Collaborate on Drug Development for Membrane Proteins - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sweden-based Salipro Biotech AB announced a research and license agreement with German pharmaceutical giant Boehringer Ingelheim. The collaboration aims to advance the development of novel drugs targeting G protein-coupled receptors (GPCRs), ion channels, transporters, and other integral membrane proteins, focusing on treatment areas such as mental health and cardio-renal-metabolic diseases.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=29245\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Salipro Biotech and Boehringer Ingelheim Collaborate on Drug Development for Membrane Proteins\" \/>\n<meta property=\"og:description\" content=\"Sweden-based Salipro Biotech AB announced a research and license agreement with German pharmaceutical giant Boehringer Ingelheim. The collaboration aims to advance the development of novel drugs targeting G protein-coupled receptors (GPCRs), ion channels, transporters, and other integral membrane proteins, focusing on treatment areas such as mental health and cardio-renal-metabolic diseases.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=29245\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-14T09:10:13+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-14T09:10:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2023\/03\/1411-png.avif\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=29245#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=29245\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Salipro Biotech and Boehringer Ingelheim Collaborate on Drug Development for Membrane Proteins\",\"datePublished\":\"2025-03-14T09:10:13+00:00\",\"dateModified\":\"2025-03-14T09:10:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=29245\"},\"wordCount\":165,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=29245#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2023\\\/03\\\/1411-png.avif\",\"keywords\":[\"Boehringer Ingelheim\",\"Salipro Biotech\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=29245#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=29245\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=29245\",\"name\":\"Salipro Biotech and Boehringer Ingelheim Collaborate on Drug Development for Membrane Proteins - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=29245#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=29245#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2023\\\/03\\\/1411-png.avif\",\"datePublished\":\"2025-03-14T09:10:13+00:00\",\"dateModified\":\"2025-03-14T09:10:17+00:00\",\"description\":\"Sweden-based Salipro Biotech AB announced a research and license agreement with German pharmaceutical giant Boehringer Ingelheim. The collaboration aims to advance the development of novel drugs targeting G protein-coupled receptors (GPCRs), ion channels, transporters, and other integral membrane proteins, focusing on treatment areas such as mental health and cardio-renal-metabolic diseases.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=29245#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=29245\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=29245#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2023\\\/03\\\/1411-png.avif\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2023\\\/03\\\/1411-png.avif\",\"width\":1080,\"height\":608,\"caption\":\"Salipro Biotech and Boehringer Ingelheim Collaborate on Drug Development for Membrane Proteins\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=29245#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Salipro Biotech and Boehringer Ingelheim Collaborate on Drug Development for Membrane Proteins\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Salipro Biotech and Boehringer Ingelheim Collaborate on Drug Development for Membrane Proteins - Insight, China&#039;s Pharmaceutical Industry","description":"Sweden-based Salipro Biotech AB announced a research and license agreement with German pharmaceutical giant Boehringer Ingelheim. The collaboration aims to advance the development of novel drugs targeting G protein-coupled receptors (GPCRs), ion channels, transporters, and other integral membrane proteins, focusing on treatment areas such as mental health and cardio-renal-metabolic diseases.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=29245","og_locale":"en_US","og_type":"article","og_title":"Salipro Biotech and Boehringer Ingelheim Collaborate on Drug Development for Membrane Proteins","og_description":"Sweden-based Salipro Biotech AB announced a research and license agreement with German pharmaceutical giant Boehringer Ingelheim. The collaboration aims to advance the development of novel drugs targeting G protein-coupled receptors (GPCRs), ion channels, transporters, and other integral membrane proteins, focusing on treatment areas such as mental health and cardio-renal-metabolic diseases.","og_url":"https:\/\/flcube.com\/?p=29245","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-03-14T09:10:13+00:00","article_modified_time":"2025-03-14T09:10:17+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2023\/03\/1411-png.avif","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=29245#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=29245"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Salipro Biotech and Boehringer Ingelheim Collaborate on Drug Development for Membrane Proteins","datePublished":"2025-03-14T09:10:13+00:00","dateModified":"2025-03-14T09:10:17+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=29245"},"wordCount":165,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=29245#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2023\/03\/1411-png.avif","keywords":["Boehringer Ingelheim","Salipro Biotech"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=29245#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=29245","url":"https:\/\/flcube.com\/?p=29245","name":"Salipro Biotech and Boehringer Ingelheim Collaborate on Drug Development for Membrane Proteins - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=29245#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=29245#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2023\/03\/1411-png.avif","datePublished":"2025-03-14T09:10:13+00:00","dateModified":"2025-03-14T09:10:17+00:00","description":"Sweden-based Salipro Biotech AB announced a research and license agreement with German pharmaceutical giant Boehringer Ingelheim. The collaboration aims to advance the development of novel drugs targeting G protein-coupled receptors (GPCRs), ion channels, transporters, and other integral membrane proteins, focusing on treatment areas such as mental health and cardio-renal-metabolic diseases.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=29245#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=29245"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=29245#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2023\/03\/1411-png.avif","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2023\/03\/1411-png.avif","width":1080,"height":608,"caption":"Salipro Biotech and Boehringer Ingelheim Collaborate on Drug Development for Membrane Proteins"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=29245#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Salipro Biotech and Boehringer Ingelheim Collaborate on Drug Development for Membrane Proteins"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2023\/03\/1411-png.avif","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/29245","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=29245"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/29245\/revisions"}],"predecessor-version":[{"id":29246,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/29245\/revisions\/29246"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/29247"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=29245"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=29245"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=29245"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}